MedTrace Logo

Erectile Rating During the Treatment of Rectal Cancers Localized

NCT01843218 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-23

Study results available
· View outcomes & findings →

Summary

Sexual dysfunction is a common side effect of medical and surgical treatments for rectal cancer. It can manifest as ejaculation disorders or erectile dysfunction. Due to the modesty of both patients and doctors, these disorders are poorly understood and probably underestimated at present. Aim : Objectively assess the presence of erectile dysfunction induced by medical and surgical treatment of rectal cancer three months after surgery. These objective data will be obtained using the RIGISCAN® PLUS system coupled with polysomnographic recording.

Conditions

  • Rectal Cancer Stage I

Interventions

OTHER

Evaluation of erectile dysfunction

Assessment (at night) of erctile dysfunction using R/P recording (RIGISCAN® PLUS / polysomonography)

Sponsors & Collaborators

  • Institut Bergonié

    lead OTHER

Principal Investigators

  • EVRARD Serge, PU-PH · Institut Bergonié

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2014-12-31
Completion
2015-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01843218 on ClinicalTrials.gov